CL2017003465A1 - Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy. - Google Patents

Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy.

Info

Publication number
CL2017003465A1
CL2017003465A1 CL2017003465A CL2017003465A CL2017003465A1 CL 2017003465 A1 CL2017003465 A1 CL 2017003465A1 CL 2017003465 A CL2017003465 A CL 2017003465A CL 2017003465 A CL2017003465 A CL 2017003465A CL 2017003465 A1 CL2017003465 A1 CL 2017003465A1
Authority
CL
Chile
Prior art keywords
treatment
epilepsy
bumetanide
homeostasis
restore
Prior art date
Application number
CL2017003465A
Other languages
Spanish (es)
Inventor
Montecinos Patricio Alejandro Rojas
Suzarte Marcelo Andrés Lara
Ponce Enrique Antonio Lorca
Lincoñir Patricia Alejandra González
Original Assignee
Univ Santiago Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Santiago Chile filed Critical Univ Santiago Chile
Priority to CL2017003465A priority Critical patent/CL2017003465A1/en
Publication of CL2017003465A1 publication Critical patent/CL2017003465A1/en
Priority to PCT/CL2018/050147 priority patent/WO2019126894A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de Cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore Cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially, in the treatment of refractory epilepsy.

CL2017003465A 2017-12-28 2017-12-28 Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy. CL2017003465A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2017003465A CL2017003465A1 (en) 2017-12-28 2017-12-28 Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy.
PCT/CL2018/050147 WO2019126894A1 (en) 2017-12-28 2018-12-26 Combined use of bumetanide with valproic acid or a pharmaceutically acceptable salt thereof in the treatment of refractory epilepsy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2017003465A CL2017003465A1 (en) 2017-12-28 2017-12-28 Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy.

Publications (1)

Publication Number Publication Date
CL2017003465A1 true CL2017003465A1 (en) 2018-08-17

Family

ID=65561328

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003465A CL2017003465A1 (en) 2017-12-28 2017-12-28 Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy.

Country Status (2)

Country Link
CL (1) CL2017003465A1 (en)
WO (1) WO2019126894A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843034B (en) * 2019-11-26 2022-08-23 亚瑟瑞智科技管理顾问股份有限公司 Composition containing clavulanic acid and valproic acid and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238622B2 (en) * 2009-07-24 2019-03-26 Wolfgang S. Mueller Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE)
US8822539B2 (en) * 2010-03-28 2014-09-02 Children's Medical Center Corporation Combination therapies: inhibitors of GABA transaminase and NKCC1

Also Published As

Publication number Publication date
WO2019126894A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
CL2020000122A1 (en) Treatment methods for cystic fibrosis.
CL2018003597A1 (en) Pyrimidin-2-ylamino-1h-pyrazoles as delrrk2 inhibitors for use in the treatment of neurodegenerative disorders.
MX2021004639A (en) COMBINATIONS OF LYSINE-SPECIFIC DEMETHYLASE-1 INHIBITORS (LSD1) FOR USE IN THE TREATMENT OF SOLID TUMORS.
MX379193B (en) SOLID SOLUTION COMPOSITIONS AND THEIR USE IN CHRONIC INFLAMMATION.
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
SV2018005610A (en) SUBSTITUTED OXOPIRIDINE DERIVATIVES
CO2017004525A2 (en) Ror-gamma inhibitory dihydropyrrolopyridines
CL2018000739A1 (en) Adjunctive therapy with 25-hydroxy vitamin d and articles of the same.
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
CO2018003224A2 (en) Modified release amino acid formulations administered orally
MX2016014564A (en) VACCINE AGAINST THE BAUMANNII ACINETOBACTER OBTAINED FROM LENT POLISHING COMPONENTS OF LIPOPOLISACARIDO.
CL2016001756A1 (en) Pharmaceutical preparation comprising 0.001-0.003 pv of 6-4-pyrazol-1-ylbenzylpyridin-3-ylsulfonylaminomethylpyridin-2-ylaminoacetate isopropyl or a salt of the same use for the treatment or prevention of glaucoma or ocular hypertension.
MX386055B (en) USE OF MEDICINES TO SLOW THE PROGRESSION OF PARKINSON'S DISEASE.
MX389178B (en) FIXED RATIO FORMULATION OF INSULIN GLARGINE/LIXISENATIDE.
CL2015001446A1 (en) Preparation procedure of human albumin with reduced dissolved oxygen level.
MX2018012285A (en) TREATMENT METHODS FOR COLESTIC AND FIBROTIC DISEASES.
CL2017001904A1 (en) Composition for the treatment of hepatic veno-occlusive disease.
DOP2016000297A (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES
MX2017000676A (en) ORITAVANCINA HIGH PURITY AND METHOD TO PRODUCE THE SAME.
AR111374A1 (en) USE OF LIK066 IN PATIENTS WITH HEART FAILURE
BR112018015367A2 (en) nanofiber oromucosal carriers for therapeutic treatment
MX389026B (en) A PHARMACEUTICAL COMPOSITION AND ITS USE.
MX2017016774A (en) THERAPEUTIC AGENT FOR FIBROSIS.
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
DOP2017000014A (en) METHODS TO IMPROVE MIOCARDIC PERFORMANCE IN PATIENTS WITH FONTAN SURGERY USING UDENAFILO COMPOSITIONS